Pfizer (PFE) is bracing for significant revenue challenges as key drugs, including Eliquis and Vyndaqel, face patent expirations in 2028. This impending loss of patent protection has led to a bearish sentiment on Wall Street regarding Pfizer’s stock, particularly as the company lacks major new drug launches to offset the revenue decline. While the company’s dividend yield stands at an impressive 6.6%, concerns arise from a payout ratio exceeding 100%, indicating potential strain on future distributions.
Despite these challenges, Pfizer’s cash flow supports its dividend, with a cash payout ratio around 100%. This suggests that, while the company is navigating headwinds, it can sustain its dividend through cash reserves or debt if necessary. Compared to the S&P 500’s yield of 1.1%, Pfizer’s dividend presents a compelling opportunity for long-term investors willing to accept some risk.
For market professionals, the key takeaway is that Pfizer’s high yield may provide an attractive risk/reward profile, particularly if the company can maintain its dividend amidst patent expirations.
Source: fool.com